Current Perspectives on Antiretroviral Therapy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Current estimates suggest that at least 1 million persons in the United States are infected with the human immunodeficiency virus (HIV), the cause of the acquired immunodeficiency syndrome. Knowledge of the life cycle of HIV has provided the fundamental information necessary to initiate programs that will identify drugs to treat the infection. Inhibition of reverse transcriptase represents the only strategy of proved clinical value. Three such drugs are available: zidovudine, didanosine, and zalcitabine. Zidovudine is the only proved agent for therapy of asymptomatic HIV infection; and for symptomatic disease, monotherapy with zidovudine must also be regarded as the first‐line approach. For patients who are intolerant, are failing clinically, or have received prior long‐term treatment with zidovudine, monotherapy with didanosine or zalcitabine, or a combination of zidovudine and zalcitabine are alternatives. Progress is being made in the treatment of HIV infection, but the considerable challenge to affect the inexorable progressive nature of HIV disease remains daunting. 1993 Pharmacotherapy Publications Inc.

Original languageEnglish (US)
Pages (from-to)627-633
Number of pages7
JournalPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume13
Issue number6
DOIs
StatePublished - Jan 1 1993

Fingerprint

Zidovudine
Zalcitabine
HIV
Virus Diseases
Didanosine
Therapeutics
RNA-Directed DNA Polymerase
Life Cycle Stages
Pharmaceutical Preparations
Publications
Acquired Immunodeficiency Syndrome
Drug Therapy
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Current Perspectives on Antiretroviral Therapy. / Fletcher, Courtney V.

In: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Vol. 13, No. 6, 01.01.1993, p. 627-633.

Research output: Contribution to journalArticle

@article{fa5f201da8114590a46ee101b7be8f80,
title = "Current Perspectives on Antiretroviral Therapy",
abstract = "Current estimates suggest that at least 1 million persons in the United States are infected with the human immunodeficiency virus (HIV), the cause of the acquired immunodeficiency syndrome. Knowledge of the life cycle of HIV has provided the fundamental information necessary to initiate programs that will identify drugs to treat the infection. Inhibition of reverse transcriptase represents the only strategy of proved clinical value. Three such drugs are available: zidovudine, didanosine, and zalcitabine. Zidovudine is the only proved agent for therapy of asymptomatic HIV infection; and for symptomatic disease, monotherapy with zidovudine must also be regarded as the first‐line approach. For patients who are intolerant, are failing clinically, or have received prior long‐term treatment with zidovudine, monotherapy with didanosine or zalcitabine, or a combination of zidovudine and zalcitabine are alternatives. Progress is being made in the treatment of HIV infection, but the considerable challenge to affect the inexorable progressive nature of HIV disease remains daunting. 1993 Pharmacotherapy Publications Inc.",
author = "Fletcher, {Courtney V.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1002/j.1875-9114.1993.tb02770.x",
language = "English (US)",
volume = "13",
pages = "627--633",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Current Perspectives on Antiretroviral Therapy

AU - Fletcher, Courtney V.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Current estimates suggest that at least 1 million persons in the United States are infected with the human immunodeficiency virus (HIV), the cause of the acquired immunodeficiency syndrome. Knowledge of the life cycle of HIV has provided the fundamental information necessary to initiate programs that will identify drugs to treat the infection. Inhibition of reverse transcriptase represents the only strategy of proved clinical value. Three such drugs are available: zidovudine, didanosine, and zalcitabine. Zidovudine is the only proved agent for therapy of asymptomatic HIV infection; and for symptomatic disease, monotherapy with zidovudine must also be regarded as the first‐line approach. For patients who are intolerant, are failing clinically, or have received prior long‐term treatment with zidovudine, monotherapy with didanosine or zalcitabine, or a combination of zidovudine and zalcitabine are alternatives. Progress is being made in the treatment of HIV infection, but the considerable challenge to affect the inexorable progressive nature of HIV disease remains daunting. 1993 Pharmacotherapy Publications Inc.

AB - Current estimates suggest that at least 1 million persons in the United States are infected with the human immunodeficiency virus (HIV), the cause of the acquired immunodeficiency syndrome. Knowledge of the life cycle of HIV has provided the fundamental information necessary to initiate programs that will identify drugs to treat the infection. Inhibition of reverse transcriptase represents the only strategy of proved clinical value. Three such drugs are available: zidovudine, didanosine, and zalcitabine. Zidovudine is the only proved agent for therapy of asymptomatic HIV infection; and for symptomatic disease, monotherapy with zidovudine must also be regarded as the first‐line approach. For patients who are intolerant, are failing clinically, or have received prior long‐term treatment with zidovudine, monotherapy with didanosine or zalcitabine, or a combination of zidovudine and zalcitabine are alternatives. Progress is being made in the treatment of HIV infection, but the considerable challenge to affect the inexorable progressive nature of HIV disease remains daunting. 1993 Pharmacotherapy Publications Inc.

UR - http://www.scopus.com/inward/record.url?scp=0027379346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027379346&partnerID=8YFLogxK

U2 - 10.1002/j.1875-9114.1993.tb02770.x

DO - 10.1002/j.1875-9114.1993.tb02770.x

M3 - Article

C2 - 7508101

AN - SCOPUS:0027379346

VL - 13

SP - 627

EP - 633

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 6

ER -